Stocks and Investing
Stocks and Investing
Thu, January 3, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, January 2, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Christopher Raymond Downgraded (VRTX) to Hold on, Jan 2nd, 2019
Christopher Raymond of Raymond James, Downgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold on, Jan 2nd, 2019.
Christopher has made no other calls on VRTX in the last 4 months.
There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 0 agree with Christopher's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Christopher
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $210 on, Wednesday, December 19th, 2018
- Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Held Target at $220 on, Friday, October 26th, 2018
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $192 on, Thursday, October 25th, 2018